178 related articles for article (PubMed ID: 31107896)
1. Associations of plasma fibroblast growth factor 23 and other markers of chronic kidney disease-Mineral and bone disorder with all-cause mortality in South African patients on maintenance dialysis: A 3-year prospective cohort study.
Waziri B; Musenge E; Duarte R; Dickens C; Dix-Peek T; Rekhviashvili V; Paget G; Naicker S
PLoS One; 2019; 14(5):e0216656. PubMed ID: 31107896
[TBL] [Abstract][Full Text] [Related]
2. Detecting high-risk chronic kidney disease-mineral bone disorder phenotypes among patients on dialysis: a historical cohort study.
Neri L; Kreuzberg U; Bellocchio F; Brancaccio D; Barbieri C; Canaud B; Stuard S; Ketteler M
Nephrol Dial Transplant; 2019 Apr; 34(4):682-691. PubMed ID: 30165528
[TBL] [Abstract][Full Text] [Related]
3. Association of Parameters of Mineral Bone Disorder with Mortality in Patients on Hemodialysis according to Level of Residual Kidney Function.
Wang M; Obi Y; Streja E; Rhee CM; Lau WL; Chen J; Hao C; Hamano T; Kovesdy CP; Kalantar-Zadeh K
Clin J Am Soc Nephrol; 2017 Jul; 12(7):1118-1127. PubMed ID: 28487345
[TBL] [Abstract][Full Text] [Related]
4. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.
Noordzij M; Korevaar JC; Boeschoten EW; Dekker FW; Bos WJ; Krediet RT;
Am J Kidney Dis; 2005 Nov; 46(5):925-32. PubMed ID: 16253734
[TBL] [Abstract][Full Text] [Related]
5. Progression of Vascular Calcification and Clinical Outcomes in Patients Receiving Maintenance Dialysis.
Zhang H; Li G; Yu X; Yang J; Jiang A; Cheng H; Fu J; Liang X; Liu J; Lou J; Wang M; Xing C; Zhang A; Zhang M; Xiao X; Yu C; Wang R; Wang L; Chen Y; Guan T; Peng A; Chen N; Hao C; Liu B; Wang S; Shen D; Jia Z; Liu Z;
JAMA Netw Open; 2023 May; 6(5):e2310909. PubMed ID: 37126347
[TBL] [Abstract][Full Text] [Related]
6. Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis.
Nakano C; Hamano T; Fujii N; Obi Y; Matsui I; Tomida K; Mikami S; Inoue K; Shimomura A; Nagasawa Y; Okada N; Tsubakihara Y; Rakugi H; Isaka Y
Bone; 2012 Jun; 50(6):1266-74. PubMed ID: 22425694
[TBL] [Abstract][Full Text] [Related]
7. Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study.
Eisenga MF; De Jong MA; Van der Meer P; Leaf DE; Huls G; Nolte IM; Gaillard CAJM; Bakker SJL; De Borst MH
PLoS Med; 2019 Jun; 16(6):e1002818. PubMed ID: 31170159
[TBL] [Abstract][Full Text] [Related]
8. Biochemical markers of mineral bone disorder in South African patients on maintenance haemodialysis.
Waziri B; Duarte R; Naicker S
Afr Health Sci; 2017 Jun; 17(2):445-452. PubMed ID: 29062340
[TBL] [Abstract][Full Text] [Related]
9. Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort.
Lamina C; Kronenberg F; Stenvinkel P; Froissart M; Forer L; Schönherr S; Wheeler DC; Eckardt KU; Floege J
Nephrol Dial Transplant; 2020 Mar; 35(3):478-487. PubMed ID: 31006013
[TBL] [Abstract][Full Text] [Related]
10. Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patients.
Bielesz BO; Hecking M; Plischke M; Cejka D; Kieweg H; Haas M; Marculescu R; Hörl WH; Bieglmayer C; Sunder-Plassmann G
Clin Biochem; 2014 Sep; 47(13-14):1316-9. PubMed ID: 24956265
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study.
Brandenburg VM; Kleber ME; Vervloet MG; Tomaschitz A; Pilz S; Stojakovic T; Delgado G; Grammer TB; Marx N; März W; Scharnagl H
Atherosclerosis; 2014 Nov; 237(1):53-9. PubMed ID: 25200615
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.
Gutiérrez OM; Mannstadt M; Isakova T; Rauh-Hain JA; Tamez H; Shah A; Smith K; Lee H; Thadhani R; Jüppner H; Wolf M
N Engl J Med; 2008 Aug; 359(6):584-92. PubMed ID: 18687639
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast Growth Factor 23 Genotype and Cardiovascular Disease in Patients Undergoing Hemodialysis.
Schwantes-An TH; Liu S; Stedman M; Decker BS; Wetherill L; Edenberg HJ; Vatta M; Foroud TM; Chertow GM; Moe SM
Am J Nephrol; 2019; 49(2):125-132. PubMed ID: 30669147
[TBL] [Abstract][Full Text] [Related]
14. Functional impairment attenuates the association between high serum phosphate and mortality in dialysis patients: a nationwide cohort study.
Wakasugi M; Kazama JJ; Wada A; Hamano T; Masakane I; Narita I
Nephrol Dial Transplant; 2019 Jul; 34(7):1207-1216. PubMed ID: 30124993
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs).
Westerberg PA; Tivesten Å; Karlsson MK; Mellström D; Orwoll E; Ohlsson C; Larsson TE; Linde T; Ljunggren Ö
BMC Nephrol; 2013 Apr; 14():85. PubMed ID: 23587028
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.
Isakova T; Xie H; Yang W; Xie D; Anderson AH; Scialla J; Wahl P; Gutiérrez OM; Steigerwalt S; He J; Schwartz S; Lo J; Ojo A; Sondheimer J; Hsu CY; Lash J; Leonard M; Kusek JW; Feldman HI; Wolf M;
JAMA; 2011 Jun; 305(23):2432-9. PubMed ID: 21673295
[TBL] [Abstract][Full Text] [Related]
17. Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study.
Fernández-Martín JL; Dusso A; Martínez-Camblor P; Dionisi MP; Floege J; Ketteler M; London G; Locatelli F; Górriz JL; Rutkowski B; Bos WJ; Tielemans C; Martin PY; Wüthrich RP; Pavlovic D; Benedik M; Rodríguez-Puyol D; Carrero JJ; Zoccali C; Cannata-Andía JB;
Nephrol Dial Transplant; 2019 Apr; 34(4):673-681. PubMed ID: 29741651
[TBL] [Abstract][Full Text] [Related]
18. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephrol Dial Transplant; 2009 Sep; 24(9):2792-6. PubMed ID: 19395730
[TBL] [Abstract][Full Text] [Related]
19. Low serum intact parathyroid hormone level is an independent risk factor for overall mortality and major adverse cardiac and cerebrovascular events in incident dialysis patients.
Lee SA; Lee MJ; Ryu GW; Jhee JH; Kim HW; Park S; Jung SY; Oh HJ; Park JT; Han SH; Kang SW; Yoo TH
Osteoporos Int; 2016 Sep; 27(9):2717-2726. PubMed ID: 27216997
[TBL] [Abstract][Full Text] [Related]
20. Lower serum fibroblast growth factor-23 levels may suggest malnutrition in maintenance haemodialysis patients.
Mizuiri S; Nishizawa Y; Yamashita K; Ono K; Oda M; Usui K; Shigemoto K
Nephrology (Carlton); 2014 Sep; 19(9):568-73. PubMed ID: 24947687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
